Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Sep;33(9):1536-1542.
doi: 10.1007/s11606-018-4389-7. Epub 2018 Mar 15.

Partners and Alerts in Medication Adherence: A Randomized Clinical Trial

Judd B Kessler  1 , Andrea B Troxel  2 , David A Asch  3   4   5   6   7 , Shivan J Mehta  5   6   7 , Noora Marcus  4 , Raymond Lim  4   5 , Jingsan Zhu  4 , William Shrank  8 , Troyen Brennan  9 , Kevin G Volpp  3   4   5   6   7
Affiliations
Randomized Controlled Trial

Partners and Alerts in Medication Adherence: A Randomized Clinical Trial

Judd B Kessler et al. J Gen Intern Med. 2018 Sep.

Abstract

Background: Poor medication adherence is common and limits the effectiveness of treatment.

Objective: To investigate how social supports, automated alerts, and their combination improve medication adherence.

Design: Four-arm, randomized clinical trial with a 6-month intervention.

Participants: A total of 179 CVS health employees or adult dependents with CVS Caremark prescription coverage, a current daily statin prescription, a medication possession ratio less than 80%, and Internet access.

Interventions: Participants were randomly assigned to control, social support (partner), automated adherence alert messages (alert), or both social support and alerts (partner + alert). Participants in the social support arms were asked to name a medication adherence partner (MAP) to help them take their medication. Participants in the alert arms were sent emails, text messages, or automated phone calls if they had failed to adhere on the previous day and on one or both of the 2 days before that. In partner + alert, both participants and fully enrolled MAPs received alerts.

Main measures: Adherence measured by wireless pill bottle opening.

Key results: Compared to 36.0% adherence in control, adherence was significantly greater in the alert arm (52.9%, difference vs. control of 17.0%, 95% CI for difference 6.3 to 27.6%, P = 0.002) and the partner + alert arm (54.5%, difference vs. control of 18.6%, 95% CI for difference 6.6 to 30.5%, P = 0.003). Adherence in the partner arm was not statistically significantly greater than control (43.2%, difference vs. control of 7.2%, 95% CI of difference - 5.2% to 19.5%, P = 0.25). There were no statistically significant differences among the three treatment arms. Fewer participants invited a MAP in the partner + alert arm than the partner arm (P = 0.02).

Conclusions: Automated alerts were effective at improving medication adherence. Assigning a medication adherence partner did not statistically significantly affect adherence rates.

Trial registration: ClinicalTrials.gov Number NCT01890018 [ https://clinicaltrials.gov /].

Keywords: medication adherence; medication alerts; support partner.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards

The study was approved by the Institutional Review Board of the University of Pennsylvania and registered on ClinicalTrials.gov (NCT01890018).

Conflict of Interest

All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs. Asch and Volpp are principals at the behavioral economics consulting firm VAL Health. Dr. Troxel serves on the scientific advisory board of VAL Health. Dr. Volpp has received consulting income from CVS Caremark and research funding from Humana, CVS Caremark, Discovery/Vitality (South Africa insurer and health incentives company, not the manufacturer of Vitality Glowcaps), Hawaii Medical Services Association, Weight Watchers, and Merck. Dr. Shrank is employed and salaried by UPMC Health Plan. Dr. Brennan is employed and salaried by CVS Health Corporation. All other authors declare no conflicts of interest.

Presentation

AcademyHealth Annual Research Meeting, June 28, 2016.

Figures

Figure 1
Figure 1
CONSORT Diagram. *After withdrawal, adherence was marked as 0 (i.e., non-adherent).
Figure 2
Figure 2
Mean weekly medication adherence by intervention group. Weekly adherence was calculated as the average of daily adherence. Green line is usual care arm (N = 34), red line is partner arm (N = 31), purple line is alert arm (N = 51), blue line is partner + alert arm (N = 46)
See this image and copyright information in PMC

References

    1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78. doi: 10.1016/S0140-6736(05)67394-1. - DOI - PubMed
    1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9 - PubMed
    1. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine. 2004;350:1495–504. doi: 10.1056/NEJMoa040583. - DOI - PubMed
    1. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462–7. doi: 10.1001/jama.288.4.462. - DOI - PubMed
    1. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842–7. doi: 10.1001/archinte.166.17.1842. - DOI - PubMed

Publication types

Substances

Associated data